Dr RR Baliga's "Got Knowledge Doc" Podkast

🧬 Prediabetes remission is not just metabolic—it's cardiovascular medicine. ❤️

A new analysis in The Lancet Diabetes & Endocrinology shows that achieving remission to normoglycaemia—not merely delaying diabetes—was associated with a ~50% reduction in cardiovascular death or heart failure hospitalisation, with benefits persisting for 20–30 years across U.S. and Chinese cohorts ⏳📉.

🔍 The message is profound and practical: normalize glucose early, protect the heart long-term. Remission may represent a measurable, durable, and globally applicable prevention target, alongside weight loss and lifestyle change.

This is prevention with a memory—and a legacy. 🧠❤️

🔬 New Insights on MASLD from JAMA 🍃

I recently reviewed an excellent JAMA article on Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)—now recognized as the most common chronic liver disease worldwide. The review highlights how metabolic dysfunction, inflammation, and fibrosis converge to drive long-term risks, including cardiovascular disease, hepatocellular carcinoma, and extrahepatic cancers.

Key advances include better noninvasive fibrosis assessment (FIB-4, elastography), strong evidence for lifestyle-driven weight loss, and new therapeutic momentum with resmetirom and semaglutide for MASH with fibrosis.

As MASLD incidence accelerates globally, this synthesis underscores the urgency of early detection, metabolic risk control, and multidisciplinary care. 🌍💡

In this week's exploration, I dive into the brain's hidden "plumbing"—the glymphatic and meningeal lymphatic systems—drawing from a remarkable report in Science magazine (Dec 2025).

The piece outlines emerging Alzheimer's strategies ranging from VEGF-C and Aquaporin-4 gene therapy to vasomotion drugs, CO₂ breathing, massage-based lymphatic stimulation, and even experimental lymphovenous surgery.

A quiet revolution is underway—hope flowing through the brain's deepest channels. 💧🌊

#Neuroscience #Alzheimers #ScienceMagazine #BrainHealth

🌍 New WHO Guidance on GLP-1 Therapies: A Turning Point in Obesity Care 💉📘

The latest JAMA report highlights a pivotal moment in global health: the WHO's evidence-informed guideline on GLP-1 therapies for adults living with obesity. With over 1 billion people affected worldwide, this chronic, relapsing disease demands integrated, equitable, lifelong care.

The guidance underscores two essentials:

💊 Long-term GLP-1 therapy for those living with obesity

🤝 Intensive behavioral support to amplify and sustain benefits

But the message is clear—medication alone is not enough. True progress requires strong health systems, equitable access, and person-centered prevention and care.

A timely call to action for clinicians, policymakers, and health leaders everywhere. 🌱🌐

Delving into the latest JAHA review on immune checkpoint inhibitors and the heart has been illuminating 🔍❤️.

As immunotherapy transforms cancer care, we're learning that unleashed T-cells can also stir the silent storms within vulnerable plaques ⚡🩺.

This piece beautifully unpacks how ICIs may accelerate atherosclerosis, heighten ACS risk, and challenge our diagnostic instincts—especially when myocarditis and ischemia mimic one another 🎯🧬.

As we push the frontier of cancer survival, cardio-oncology must rise in parallel: better surveillance, smarter risk reduction, and deeper mechanistic insight 🚀📚.

A timely reminder that curing cancer and protecting the heart must go hand in hand 🤝❤️‍🔥.

Immanuel Kant: The Architect of Modern Reason 🧠✨

Fascinating to revisit Kant's legacy — the thinker who reshaped how we understand knowledge, morality, and human freedom. His ideas on autonomy, duty, and the categorical imperative continue to guide ethical reasoning in science, leadership, and society.

From Critique of Pure Reason to Perpetual Peace, Kant invites us to think boldly:

What can I know? What should I do? What may I hope? 🌍📚

His work still challenges us to act with integrity, respect human dignity, and build a more rational and just world.

#Kant #Enlightenment #Ethics #Reason #Leadership #Philosophy 🕊️

🚀 Immune checkpoint inhibitors have transformed cancer care—but they come with a cardiovascular shadow.

A new International Cardio-Oncology Society (IC-OS) position statement offers the clearest guidance yet on myocarditis, pericarditis, arrhythmias, ACS, and noninflammatory HF linked to ICI therapy. 🫀💡

Key insights include:

• Early recognition with troponin, ECG, and CMR 🧪📊

• Smoldering vs. nonsevere vs. fulminant myocarditis distinctions 🔍

• Steroid-first management and the evolving role of abatacept + JAK inhibitors 💊

• Nuanced approaches to ICI rechallenge when cancer control demands it 🔄🎯

• The essential role of multidisciplinary cardio-oncology teams 🤝

This is a must-read for anyone navigating the intersection of oncology, cardiology, and immunotherapy. 🌐🔥

Chronic kidney disease now affects nearly 850 million people worldwide, yet early detection and simple, evidence-based interventions can dramatically change the trajectory of both kidney and cardiovascular health. 🌍🩺

The latest Lancet Seminar highlights powerful tools—eGFR + albuminuria staging, SGLT2 inhibitors, RAS blockade, statins, and GLP-1 therapies—that allow every clinician to make a measurable impact. 💊📉

A reminder that timely action is kidney protection. 💧✨

🚀 New insights from Cell shine a light on an unexpected ally in the fight against cognitive decline. A natural experiment from Wales shows that the shingles (herpes zoster) vaccine doesn't just prevent viral reactivation—it may also reduce new mild cognitive impairment and lower dementia-related mortality over long-term follow-up.

🔍 Using a strict birthday-based eligibility cutoff, the study provides causal evidence—rare in population dementia research—that vaccination may slow disease across its entire course.

🧠✨ As we rethink neuroinflammation, immunosenescence, and healthy aging, this work opens the door to exploring broader neuroprotective effects of adult vaccines.

📄 A reminder that sometimes the smallest public health interventions carry the biggest, most surprising benefits.

📘 New NEJM Evidence for the 2025–26 Vaccine Season is out—and it delivers clarity at a time we need it most.

The systematic review of 511 studies shows strong, consistent protection against hospitalization from Covid-19, RSV, and Influenza, with reassuring safety profiles across age groups. 💉🛡️

Key insights: improved VE for updated Covid-19 strains, high efficacy of maternal RSV vaccination and nirsevimab for infants, and solid influenza performance. 📊👶

A valuable guide for clinicians, health systems, and policymakers as we prepare for the upcoming respiratory season. 🌐🏥